News - Pfizer, Rare diseases

Filter

Current filters:

PfizerRare diseases

Popular Filters

1 to 25 of 29 results

Negative NICE appraisal of Pfizer’s Bosulif for CML

Negative NICE appraisal of Pfizer’s Bosulif for CML

27-11-2013

UK drug watchdog the National Institute for Health and Care Excellence (NICE) has issued final guidance…

BosulifEuropeOncologyPfizerPharmaceuticalPricingRare diseasesRegulation

Repligen gets first milestone under SMA deal with Pfizer

05-09-2013

USA-based Repligen (Nasdaq: RGEN) says it has received a $1 million milestone payment from global drugs…

FinancialLicensingPfizerPharmaceuticalRare diseasesRepligen

Protalix BioTherapeutics enters Gaucher drug Uplyso deal with Brazil's Ministry of Health

19-06-2013

Israel-based Protalix BioTherapeutics (TASE:PLX) has entered into a supply and technology transfer agreement…

FiocruzMarkets & MarketingPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesSouth AmericaUplyso

Pfizer and Protalix' Gaucher drug Uplyso approved in Brazil

19-03-2013

US drugs behemoth Pfizer (NYSE: PFE) and Israel-based Protalix BioTherapeutics (NYSE MKT:PLX) said that…

BiotechnologyElelysoPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesRegulationSouth AmericaUplyso

Repligen in $70 million deal with Pfizer for SMA program

04-01-2013

USA-based Repligen (Nasdaq: RGEN) saw its share jump 5.6% to $6.63, after the company revealed it has…

BiotechnologyLicensingNeurologicalPfizerPharmaceuticalRare diseasesRepligenRG3039

Protalix and Pfizer expand Elelyso agreement

07-12-2012

Israeli drug developer Protalix BioTherapeutics (NYSE-AMEX: OLX) said yesterday that it has entered into…

ElelysoLicensingPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesResearch

Pfizer in $58 million drug discovery accord on cystic fibrosis

19-11-2012

The USA-based Cystic Fibrosis Foundation Therapeutics (CFFT), the non-profit drug discovery and development…

PfizerPharmaceuticalRare diseasesResearch

Pfizer 3rd-qtr profits slump on lower than expected sales; EU says "no" to Gaucher drug

02-11-2012

US pharma behemoth Pfizer (NYSE: PFE) saw it shares fall 1.1% to $24.59 in morning trading yesterday,…

EuropeFinancialPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesRegulationtaliglucerase

FDA nod for Pfizer's rare leukemia drug Bosulif

06-09-2012

In a third cancer drug approval in just over a year for drugs behemoth Pfizer (NYSE: PFE), the US Food…

BosulifbosutinibNorth AmericaOncologyPfizerPharmaceuticalRare diseasesRegulation

US FDA calls for more efficacy data on Pfizer's tafamidis NDA

19-06-2012

The US Food and Drug Administration yesterday issued a complete response letter regarding drugs behemoth…

North AmericaPfizerPharmaceuticalRare diseasesRegulationtafamidisVyndaqel

$25 million milestone for Protalix following US approval of Elelyso

13-06-2012

Israel-based Protalix BioTherapeutics (TASE:PLX) has received a $25 million milestone payment from global…

ElelysoFinancialPfizerPharmaceuticalProtalix BioTherapeuticsRare diseases

FDA advisory panel gives mixed views on Pfizer's tafamidis

25-05-2012

The US Food and Drug Administration's peripheral and Central Nervous System Drugs Advisory Committee…

North AmericaPfizerPharmaceuticalRare diseasesRegulationtafamidisVyndaqel

FDA expands Levemir use to young children; negative on tafamidis

23-05-2012

Denmark-based global insulin giant Novo Nordisk (NOV: N) says that the US Food and Drug Administration…

DiabetesLevemirNorth AmericaNovo NordiskPfizerPharmaceuticalRare diseasesRegulationtafamidisVyndaqel

Complete responses in Phase I trial of crizotinib in rare childhood cancer

18-05-2012

A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early…

crizotinibKalkoriOncologyPfizerPharmaceuticalRare diseasesResearch

Elelyso: a new therapeutic option for patients with Gaucher disease

09-05-2012

The US Food and Drug Administration recently approved Protalix BioTherapeutic's (NYSE-AMEX: OLX) Elelyso…

CerezymeElelysoGenzymeMarkets & MarketingPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesShireVpriv

Pfizer's Elelyso approved in USA for Gaucher disease; Celebrex settlement

02-05-2012

The US Food and Drug Administration yesterday approved Elelyso (taliglucerase alfa) for injection, an…

Anti-Arthritics/RheumaticsCelebrexElelysoLegalNorth AmericaPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesRegulationtaliglucerase

Germany's IQWiG finds some benefit for Pfizer orphan drug Vyndaqel

11-04-2012

The German Institute for Quality and Efficiency in Health Care (IQWiG) has assessed Vyndaqel (tafamidis),…

EuropePfizerPharmaceuticalPricingRare diseasesRegulationVyndaqel

FDA now accepts Pfizer’s tafamidis NDA

16-02-2012

Having around a year ago issued a refuse to file letter (The Pharma Letter April 5, 2011), the US Food…

North AmericaPfizerPharmaceuticalRare diseasesRegulationtafamidisVyndaqel

Pfizer’s Vyndaqel, first drug to treat rare and fatal disease TTR-FAP, approved in Europe

18-11-2011

Following a positive opinion from an advisory committee in the summer (The Pharma Letter July 23), the…

EuropePfizerPharmaceuticalRare diseasesRegulationtafamidisVyndaqel

FDA approves Incytes’ Jakafi, first drug to treat MF; advisory panel backs Pfizer’s Prevnar 13 for adults

17-11-2011

USA-based Incyte (Nasdaq: INCY) saw its shares rise 10% to$13.90 on the news that the Food and Drug Administration…

BiotechnologyIncyteJakafiNorth AmericaNovartisPfizerPharmaceuticalPrevnarRare diseasesRegulationruxolitinibVaccines

1 to 25 of 29 results

Back to top